The alliance extends Insilico's PandaOmics and Chemistry42 platforms into pharmaceutical manufacturing for the first time, targeting a $168B CDMO industry.
AI is reshaping pharmaceutical R&D from target identification through clinical trial optimization, compressing drug discovery timelines and unlocking therapeutic targets…
Owkin and AstraZeneca are expanding their AI collaboration to develop new drug discovery models using federated learning, a technique that…